Insulin Family advanced
Insulin Cardiovascular Outcomes
Cardiovascular safety and outcomes data for insulin analogues from large randomized controlled trials.
By Encyclopeptide Editorial | 1 min read
insulin cardiovascular CVOT safety diabetes
Overview
Cardiovascular outcome trials have established the cardiovascular safety of modern insulin analogues, with some suggesting potential cardiovascular benefits.
Key Trials
ORIGIN Trial (Insulin Glargine)
- Design: 12,537 patients with CV risk factors
- Result: Neutral CV outcome (HR 1.02, 95% CI 0.94-1.11)
DEVOTE Trial (Insulin Degludec)
- Design: 7,637 patients with type 2 diabetes and high CV risk
- Result: Non-inferior for MACE (HR 0.91, 95% CI 0.78-1.06)
Clinical Implications
Modern insulin analogues are considered cardiovascularly safe, allowing clinicians to prescribe based on efficacy, hypoglycemia risk, and patient preference.
Chemical Identity
| Property | Value |
|---|---|
| Name | Insulin Cardiovascular Outcomes |
| Category | Insulin Family |
References
- Encyclopeptide Database. “Insulin Cardiovascular Outcomes” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Cardiovascular Outcomes with interactive quizzes on Wikipept.
Take a Quiz on Wikipept